Celltrion Healthcare Co., Ltd.
091990
Pozycja w akcjach
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Cena akcji
$57.75
Ostatnia synchronizacja: 2024-01-11
Kapitalizacja rynkowa
$9.42B
Zmiana (1 dzień)
-0.25%
Zmiana (1 rok)
0.00%
Kraj
KR
Handel Celltrion Healthcare Co., Ltd. (091990)
Kategoria
Healthcare
Zyski dla Celltrion Healthcare Co., Ltd. (091990)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Celltrion Healthcare Co., Ltd., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Celltrion Healthcare Co., Ltd. od 2014 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2022 | $181.92M | 9.09% |
| 2021 | $166.76M | -42.47% |
| 2020 | $289.85M | 344.13% |
| 2019 | $65.26M | 197.71% |
| 2018 | $21.92M | -89.23% |
| 2017 | $203.63M | 49.87% |
| 2016 | $135.87M | 58.71% |
| 2015 | $85.60M | 781.80% |
| 2014 | $9.71M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
